Britain's GlaxoSmithKline (GSK.L) sought to bolster its cancer business by agreeing a $1.9 billion deal to buy U.S. drug developer Sierra Oncology (SRRA.O), the latest move to fend off pressure from activist shareholder Elliott.

Comment